Diabetes research and clinical practiceHumansDiabetes MellitusType 2Sitagliptin PhosphateMale
Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin.
Yoshihiro Iwasaki, Takenobu Shimada, Takefumi Kishimori, Takao Kato, Jumpei Koike, Takehiro Matsumoto, Takafumi Yagi, Masaharu Okada
Published: 202610.1016/j.diabres.2025.113072
Abstract
AIMS: To elucidate the overall protective effects of tirzepatide against atherosclerosis-related events, including cardiovascular and lower-extremity events. METHODS: We conducted a retrospective cohort study using the TriNetX global health research…
Preview only. Read the full abstract at the source